- Trials with a EudraCT protocol (24)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
24 result(s) found for: Macrophage inflammatory protein.
Displaying page 1 of 2.
EudraCT Number: 2013-000883-27 | Sponsor Protocol Number: Rif_CVID_260611 | Start Date*: 2013-08-16 |
Sponsor Name:Oslo University hospital | ||
Full Title: EFFECTS OF RIFAXIMIN, BY MODULATION OF THE GUT MICROBIOTA, ON MARKERS OF SYSTEMIC INFLAMMATION IN PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY - AN EXPLORATORY OPEN-LABEL RANDOMIZED CONTROLLED TRIAL | ||
Medical condition: Adult patients with the diagnosis of Common variable deficiency and fulfill the inclusion and exclusion criteria, will be invited to participate in the study. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005036-26 | Sponsor Protocol Number: FXT-05 | Start Date*: 2011-11-29 | ||||||||||||||||||||||||||
Sponsor Name:Funxional Therapeutics Ltd | ||||||||||||||||||||||||||||
Full Title: An Exploratory Phase IIa Study to Investigate the Biological Activity of Oral FX125L in Adult Patients with Chronic Inflammatory Disease | ||||||||||||||||||||||||||||
Medical condition: Asthma Chronic obstructive pulmonary disease Rheumatoid arthritis Psoriasis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005787-22 | Sponsor Protocol Number: EP395-003 | Start Date*: 2022-07-21 | |||||||||||
Sponsor Name:EpiEndo Pharmaceuticals | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled study to investigate the safety and tolerability of EP395 in patients with chronic obstructive pulmonary disease (COPD) | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022042-24 | Sponsor Protocol Number: Statin_p.aeruginosa | Start Date*: 2010-12-24 | |||||||||||
Sponsor Name:NHS Lothian [...] | |||||||||||||
Full Title: A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis in patients with Pseudomonas Aeruginosa | |||||||||||||
Medical condition: The aim of this randomized double blind controlled study is to evaluate the efficacy of a 3 months treatment with atorvastatin versus placebo in patients with clinically significant bronchiectasis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004750-24 | Sponsor Protocol Number: 2013003 | Start Date*: 2014-03-17 | |||||||||||
Sponsor Name:Rode Kruis Ziekenhuis | |||||||||||||
Full Title: Omega-3 fatty acids in bariatric gastric bypass surgery: effects on liver volume, immune response and erythrocyte function | |||||||||||||
Medical condition: Patients qualified for bariatric surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001625-16 | Sponsor Protocol Number: PBI-4050-ATX-9-05 | Start Date*: 2015-10-29 | |||||||||||
Sponsor Name:ProMetic BioSciences Inc. | |||||||||||||
Full Title: A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 and of its Effects on the Inflammatory, Fibrosis,Diabetes and Obesity Biomarkers in Subjects with Alström... | |||||||||||||
Medical condition: Alström Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000868-18 | Sponsor Protocol Number: 202018 | Start Date*: 2019-12-02 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in par... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) PL (Completed) LT (Completed) ES (Completed) BE (Completed) CZ (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000971-34 | Sponsor Protocol Number: 01052013 | Start Date*: 2013-08-01 | |||||||||||
Sponsor Name:Jørgen Agnholt | |||||||||||||
Full Title: Mucosal immune regulation by high dose vitamin D treatment in Crohn’s disease | |||||||||||||
Medical condition: Active Crohn's Disease in colon and/or terminal ileum | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001428-38 | Sponsor Protocol Number: RRK2939 | Start Date*: 2006-09-18 |
Sponsor Name:University Hospitals Birmingham NHS Foundation Trust | ||
Full Title: Remission Induction in Very Early Rheumatoid Arthritis (RIVERA): a comparison of etanercept plus methotrexate plus steroid with standard therapy | ||
Medical condition: Patients with early inflamatory arthritis (duration of symptoms of < 12 weeks) who are at very high risk of the development of rheumatoid arthritis (seropositivity for Rheumatoid factor and anti-C... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000328-85 | Sponsor Protocol Number: FINNHT1 | Start Date*: 2017-05-18 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Helsinki University Hospital, Obstetrics and Gynecology | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Randomized comparative trial between abrupt and tapered mode of discontinuation of longterm hormone therapy: Impact on endothelial function, recurrence of vasomotor symptoms and quality of life | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: We will assess the effects of hormone therapy termination on endothelial function using biophysical (flow-mediated dilation, peripheral artery tonometry) and biochemical markers. We will compare th... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FI (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005747-29 | Sponsor Protocol Number: BP20843 | Start Date*: 2007-03-14 | ||||||||||||||||
Sponsor Name:F. HOFFMANN-LA ROCHE LTD | ||||||||||||||||||
Full Title: Evaluation of the relationship between HDL quantity and HDL functionality in patients treated with HDL-C raising drugs | ||||||||||||||||||
Medical condition: Primary hypercholesterolemia or mixed dyslipidemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017825-21 | Sponsor Protocol Number: EC09/081 | Start Date*: 2012-11-19 | |||||||||||
Sponsor Name:INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD | |||||||||||||
Full Title: Prospective, randomised, double-blind study to evaluate the efficacy of treatment with melatonin in adult patients with severe sepsis or septic shock. | |||||||||||||
Medical condition: Severe sepsis or septic shock. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000867-26 | Sponsor Protocol Number: 201791 | Start Date*: 2019-12-10 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study, comparing GSK3196165 with placebo and with tofacitinib in combination with conventional synthetic DMARDs, in pa... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) PL (Prematurely Ended) BG (Prematurely Ended) EE (Completed) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000797-39 | Sponsor Protocol Number: 201790 | Start Date*: 2019-11-22 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study comparing GSK3196165 with placebo and with tofacitinib, in combination with methotrexate in participants with mo... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) LV (Completed) ES (Completed) PL (Completed) LT (Completed) CZ (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000641-33 | Sponsor Protocol Number: PAX | Start Date*: 2022-04-21 | |||||||||||
Sponsor Name:Fundació FLS de Lluita contra la Sida, les Malalties Infeccioses i la Promoció de la Salut i La Ciència | |||||||||||||
Full Title: Plasma Exchange Therapy for Post- COVID-19 Condition: A Pilot, Randomized Double-Blind Study | |||||||||||||
Medical condition: Post-Acute-Covid-19 Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023562-51 | Sponsor Protocol Number: BT-CL-PGG-CRC1031 | Start Date*: 2011-11-17 | |||||||||||
Sponsor Name:Biothera | |||||||||||||
Full Title: A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination with Cetuximab (Erbitux®) in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer | |||||||||||||
Medical condition: Recurrent or Progressive KRAS Wild Type Colorectal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001635-21 | Sponsor Protocol Number: VIA-2291-02 | Start Date*: 2006-12-21 | |||||||||||
Sponsor Name:VIA PHARMACEUTICALS, INC. | |||||||||||||
Full Title: A Phase 2 Randomised, Double-blind, Placebo-controlled Study of the Effects of VIA-2291, a 5-lipoxygenase Inhibitor, on Atherosclerotic Plaque and Biomarkers of Vascular Inflammation in Patients wi... | |||||||||||||
Medical condition: Carotid Stenosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001254-22 | Sponsor Protocol Number: SARPAC | Start Date*: 2020-03-24 | |||||||||||
Sponsor Name:University Hospital Ghent | |||||||||||||
Full Title: A prospective, randomized, open-label, interventional study to investigate the efficacy of sargramostim (Leukine®) in improving oxygenation and short- and long-term outcome of COVID-19 patients wit... | |||||||||||||
Medical condition: Acute hypoxic respiratory failure of COVID-19 patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006644-19 | Sponsor Protocol Number: CRISTAL | Start Date*: 2009-01-29 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA SAN GERARDO DI MONZA | |||||||||||||
Full Title: Evaluation of inflammatory immune parameters predicting cardiovascular risk in HIV-1-infected antiretroviral therapy naive patients treated with atazanavir/ritonavir versus lopinavir/ritonavir base... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002340-40 | Sponsor Protocol Number: A9111004 | Start Date*: 2014-10-16 | |||||||||||
Sponsor Name:Pfizer Limited | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled 2-Way Crossover Study to Evaluate the Efficacy, Safety and Tolerability of PF-03715455 Administered Twice Daily By Inhalation for 4 Weeks in Subjects ... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
